Related Experiment Video

Updated: Jun 24, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

[Awareness in patients with mild cognitive impairment (MCI)]

M Dekkers1, E W A Joosten-Weyn Banningh, P A T M Eling

  • 1Verpleeghuis Zevenaar, Postbus 9000, 6900 GA Zevenaar. myrthedekkers@live.nl

Tijdschrift Voor Gerontologie En Geriatrie
|March 31, 2009
PubMed

Insights

Mild Cognitive Impairment (MCI) patients show diminished awareness of their memory deficits, a potential early dementia predictor. This lack of insight was measured using the IQCODE-N, highlighting a key difference from healthy individuals.

Area of Science:

  • Neurology
  • Psychology
  • Gerontology

Context:

  • Mild Cognitive Impairment (MCI) is a significant risk factor for dementia.
  • Awareness of deficits is a key symptom and potential early predictor of dementia.
  • Assessing patient-partner discrepancy in perceived memory problems can reveal awareness levels.

Purpose:

  • To investigate awareness of cognitive deficits in MCI patients.
  • To determine if awareness of deficits predicts dementia development.
  • To utilize the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE-N) to assess awareness.

Summary:

  • MCI patients (n=61) exhibited a significantly higher discrepancy score between self and partner assessment of cognitive decline using IQCODE-N compared to healthy controls (n=40).
  • This suggests diminished awareness of deficits in a majority (60%) of MCI patients.
  • Patients with disturbed awareness scored significantly lower on the Mini-Mental State Examination (MMSE).

Impact:

  • Diminished awareness in MCI patients is a quantifiable phenomenon.
  • Awareness deficits may serve as an early indicator for dementia progression.
  • Findings support the use of awareness assessment in early dementia detection strategies.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
High-Level and Low-Level Awareness01:19

High-Level and Low-Level Awareness

Controlled processes in human consciousness represent high-alert mental states where individuals deliberately focus their attention on achieving specific goals. Controlled processes can be seen in situations like mastering new technology, where a person might become so absorbed that they ignore surrounding distractions. Such processes involve selective attention, requiring one to concentrate on particular elements of experience while disregarding others. These are governed by executive...